Collecting and preserving glioblastoma tissue during surgery for future research
Official title: Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue (PRESERVE GBM)
Run by Baptist Health South Florida · NCT05756985 · Data updated 2026-11-12
This study is collecting and saving glioblastoma tumor tissue and blood samples during surgery to help researchers learn more about the disease and find better treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Baptist Health South Florida Academic / other |
| Locations | 1 site (Miami, Florida) |
| Status | Recruiting |
| Started | December 11, 2024 |
| Main results expected | January 2027 |
| Study ends | January 2029 |
| Registry record updated | February 4, 2026 |
| Trial ID | NCT05756985 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with high-grade glioma on MRI or those with a confirmed diagnosis of glioblastoma or gliosarcoma undergoing repeat tumor resection.
✕Probably not a fit
Patients with medical conditions or therapies that could confound study results or are not in their best interest may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to collect and preserve glioblastoma tissue during standard tumor resection surgeries, along with blood samples for molecular and genetic testing. Researchers will gather tissue from three different regions of the tumor to analyze variations in structure, DNA, and RNA. The collected data will be compared with imaging results from medical records to enhance understanding of glioblastoma biology. Ultimately, this research seeks to inform the development of new therapies for glioblastoma treatment.
Why it matters
Potential benefit: If successful, this study could lead to improved therapies for glioblastoma patients by enhancing our understanding of tumor biology.
How similar studies have gone: While this approach of specimen banking is common, the specific focus on glioblastoma tissue variation and its correlation with imaging data is a novel aspect that has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Have the appearance of high-grade glioma on magnetic resonance (MR) imaging if allowed to consent and will undergo the procedure if the frozen is consistent with glioblastoma or gliosarcoma OR Patients with a history of histologically confirmed diagnosis of World Health Organization Grade glioblastoma or gliosarcoma that are undergoing repeat resection of a recurrent tumor as identified on preoperative MR imaging 2. Aged ≥ 18 years old 3. Contrast-enhancing tumor volume of at least 10 cc on the preoperative, volumetric MRI within 1 month prior to surgery 4. Provision of signed and dated informed consent form by participant or legally authorized representative (LAR), if applicable Exclusion Criteria: 1\. Has a history or current evidence of any medical condition, therapy, or laboratory abnormality that might confound the results of the study or is not in the best interest of the participant, in the opinion of the treating investigator.
Where it's running
-
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, United States Recruiting
Study contacts
- Principal investigator: Manmeet S Ahluwalia, M.D. — Miami Cancer Institute at Baptist Health, Inc.
- Study coordinator: Manmeet S Ahluwalia, M.D.
- Email: manmeeta@baptisthealth.net
- Phone: (786) 596-2000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ERAS-801 for operable or recurrent EGFR-altered IDH-wildtype Grade IV glioblastoma or astrocytoma
This trial tests ERAS-801, a brain-penetrant EGFR blocker, to see if it is safe and changes tumor metabolism in adults with resectable or recurrent IDH-wildtype Grade IV glioblastoma or astrocytoma that have EGFR amplification or mutation.
-
Adding ruxolitinib to standard radiation and temozolomide for newly diagnosed glioblastoma
This trial will try whether adding the oral drug ruxolitinib to standard radiation and temozolomide helps adults newly diagnosed with glioblastoma.
-
Testing new drug combinations for glioblastoma treatment
This study is testing new combinations of drugs to see if they can safely help people with recurrent or newly diagnosed glioblastoma, an aggressive type of brain cancer.
-
Evaluating Bevacizumab with Focused Ultrasound for Recurrent Glioblastoma
This study is testing if adding focused ultrasound to the standard treatment of Bevacizumab can help people with recurrent glioblastoma feel better and live longer.
-
Neoadjuvant radiochemotherapy for glioblastoma treatment
This study is testing a new combination of radiation and chemotherapy before surgery to see if it helps people with glioblastoma feel better and live longer compared to standard treatment.
-
Lorlatinib for newly diagnosed high-grade glioma with ALK or ROS1 fusions
This trial will test whether the oral medicine lorlatinib helps children and young adults (ages 1–21) with newly diagnosed high-grade gliomas that have ALK or ROS1 fusions, given alone, with chemotherapy, or after radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.